BRIEF published on 04/29/2026 at 13:05, 8 days 21 hours ago Cheplapharm Sees Revenue Growth in 2025 Pharmaceutical Industry Revenue Growth EBITDA Margin Financial Stability CHEPLAPHARM
PRESS RELEASE published on 04/29/2026 at 13:00, 8 days 21 hours ago CHEPLAPHARM reports Revenue Growth in the 2025 Financial Year CHEPLAPHARM reports 8.1% revenue growth reaching €1.66 billion in FY2025. EBITDA at €642.8 million with a 38.8% margin. Employee count up 2% to 799 Financial Results EBITDA Revenue Growth CHEPLAPHARM Employee Count
BRIEF published on 02/02/2026 at 15:41, 3 months 5 days ago CHEPLAPHARM's Successful €950m Bond Issuance Refinancing Bond Issuance Financial Strategy Investor Demand CHEPLAPHARM
PRESS RELEASE published on 02/02/2026 at 15:36, 3 months 5 days ago Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed CHEPLAPHARM successfully refinances with new 6.750% bond oversubscribed multiple times, enhancing financial flexibility and maturity profile Refinancing Oversubscribed Financial Flexibility CHEPLAPHARM 6.750% Bond
BRIEF published on 08/27/2025 at 13:34, 8 months 11 days ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
PRESS RELEASE published on 08/27/2025 at 13:29, 8 months 11 days ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 10 months 11 days ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 10 months 11 days ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 11 months 5 days ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
PRESS RELEASE published on 06/02/2025 at 10:29, 11 months 5 days ago Sandra Schröder joins CHEPLAPHARM’S Management Team as VP Scientific Sandra Schröder appointed as VP Scientific at CHEPLAPHARM, responsible for scientific areas globally. Brings 25 years of experience from F. Hoffmann-La Roche AG Pharmaceutical Industry Management CHEPLAPHARM Sandra Schröder VP Scientific
Published on 05/08/2026 at 01:50, 8 hours 27 minutes ago Apex Critical Metals Announces Grant of Stock Options and RSUs
Published on 05/08/2026 at 00:45, 9 hours 32 minutes ago Route1 Announces First Quarter 2026 Financial Results Notification
Published on 05/08/2026 at 00:00, 10 hours 17 minutes ago Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 10 hours 47 minutes ago Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 11 hours 2 minutes ago BULGOLD Adopts Semi-Annual Financial Reporting
Published on 05/08/2026 at 10:08, 8 minutes ago Previewing the Product Logic Behind Waton’s Next AI Trading Platform
Published on 05/08/2026 at 10:00, 17 minutes ago Sto SE & Co. KGaA: Unfavourable weather conditions and construction downturn at the start of the year impact business development in the first quarter of 2026
Published on 05/08/2026 at 10:00, 17 minutes ago swissnet Group Signs Framework Agreement for Intelligent Video Solutions in the Smart Environment Sector
Published on 05/08/2026 at 09:44, 32 minutes ago Turkiye Garanti Bankasi A.S.: Task Allocation of Investor Relations Unit
Published on 05/07/2026 at 19:15, 15 hours 2 minutes ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:06, 15 hours 11 minutes ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 18:17, 16 hours ago DESCRIPTION OF THE LOUIS HACHETTE GROUP SHARE BUYBACK PROGRAM 2026-2027
Published on 05/07/2026 at 17:45, 16 hours 32 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
